DNMT3A and cancer: Aberrant DNA methylation has been established as key molecular events contributing to tumorigenesis, and targeting DNMT1, DNMT3A, and DNMT3B with 5-azacytidine (Aza) and 5-Aza-2’-deoxycytidine were suggested as promising strategies for cancer treatment31.